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Increased tissue status of the long-chain n-3 polyunsaturated fatty acids (LC n-3 PUFA), eicosapentaenoic (EPA) and docosahexaenoic acid (DHA) is
associated with cardiovascular and cognitive benefits. Limited epidemiological and animal data suggest that flavonoids, and specifically anthocyanins, may
increase EPA and DHA levels, potentially by increasing their synthesis from the shorter-chain n-3 PUFA, α-linolenic acid. Using complimentary cell, rodent and
human studies we investigated the impact of anthocyanins and anthocyanin-rich foods/extracts on plasma and tissue EPA and DHA levels and on the expression
of fatty acid desaturase 2 (FADS2), which represents the rate limiting enzymes in EPA and DHA synthesis. In experiment 1, rats were fed a standard diet
containing either palm oil or rapeseed oil supplemented with pure anthocyanins for 8 weeks. Retrospective fatty acid analysis was conducted on plasma samples
collected from a human randomized controlled trial where participants consumed an elderberry extract for 12 weeks (experiment 2). HepG2 cells were cultured
with α-linolenic acid with or without select anthocyanins and their in vivo metabolites for 24 h and 48 h (experiment 3). The fatty acid composition of the cell
membranes, plasma and liver tissues were analyzed by gas chromatography. Anthocyanins and anthocyanin-rich food intake had no significant impact on EPA or
DHA status or FADS2 gene expression in any model system. These data indicate little impact of dietary anthocyanins on n-3 PUFA distribution and suggest that
the increasingly recognized benefits of anthocyanins are unlikely to be the result of a beneficial impact on tissue fatty acid status.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).Keywords: Anthocyanins; n-3 PUFA; Liver; Rat; Human1. Introduction
Although not fully consistent, there are substantial data to indicate
that increased dietary intake and tissue status of the long-chain n-3
polyunsaturated fatty acid (LC n-3 PUFA), eicosapentaenoic acid
(C20:5-n3; EPA) and docosahexaenoic acid (C22:6n3; DHA) are
associated with cardiovascular and cognitive benefits [1–3]. While a
minimum intake of 0.5 g EPA+DHA per day is currently typically
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b0.05 g per day consumed by a large proportion of adult populations,
i.e., N10-fold lower than the minimum recommended intake [6,7].
Accessibility, affordability and palatability of fish products are often
cited as reasons for low EPA and DHA intakes [8]. Also, sustainability
of fish stocks is of major concern, with the current production of 1
million tons of fish oils per year insufficient to meet recommended
intakes. Therefore alternative strategies to increase EPA+DHA status
are needed.
In mammals, EPA and, to a lesser extent, DHA can be synthesized
from the shorter-chain plant derived n-3 PUFA, α-linolenic acid
(C18:3n-3; ALA) (Fig. 1), with the biosynthesis occurring predomi-
nantly in the liver. With the exception of premenopausal women, in
whomtheconversionof 18:3n-3 to 20:5n-3 and22:6n-3 is substantially
greater, the bioconversion of ALA is usually inefficient and does not
exceed 0.2%–6% for EPA and 0.1% for DHA [9]. Limited evidence is
suggestive that plant-derived bioactives may increase the conversion
efficiency. Vegetarians, and vegans have adequate status despite
negligible intake [7]. In observational studies, alcoholic beverages ander the CC BY license (http://creativecommons.org/licenses/by/3.0/).
Fig. 1. Synthesis of long-chain PUFA from linoleic (LA) acid and ALA (n-3). Both LA (n-6) and ALA (n-3) are elongated, desaturated and β-oxidized using the same enzyme system.
AA, arachidonic acid.
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associatedwith increased LCn-3 PUFA status [10–13]. In a feeding study
in rats, the inclusion of ACNs (found in red grapes, red wine and berry
fruits) in the diet was associatedwith 20%–35% and 10%–20% increased
plasma EPA and DHA [14] with the authors suggesting that increased
bioconversion of ALA to EPA+DHA may be partly responsible (Fig. 1).
More recently, rats fed with ACN-rich grape–bilberry juice for 10 weeks
had an increased overall percentage of PUFAs and a decreased percentage
saturated fatty acids (SFAs) in plasma. However, no signification impact
on LC n-3 PUFA concentrations were observed [15].
Using rodent studies,we investigated the impact of flavonoids/ACNs
on EPA and DHA status in plasma, and for the first time in liver tissue,
with hepatic gene expression of fatty acid desaturase 2 (FADS2), the
rate-limiting enzyme in the ALA to EPA and DHA bioconversion
pathway (Fig. 1) also investigated. Stored samples from a previously
completed randomized controlled trial [16] in our laboratory were
analyzed to establish the impact of an ACN-rich food extract on LC n-3
PUFA status in humans. Finally, cell culture studies in HepG2 cells were
used to explore the effect of a range of ACNs and their metabolites on
fatty acid status and FADS2 gene expression.
2. Methods and materials
2.1. Chemicals and reagents
Bovine serum albumin (BSA; fatty acid free), ALA, DHA, EPA, nonadecanoic acid
(19:0), tridecanoic acid, gallic acid (GA), p-coumaric acid (PCA), syringic acid (SYA),
butylated hydroxytoluene (BHT), potassium chloride and potassium bicarbonate were
obtained from Sigma-Aldrich. Thin layer chromatography (TLC) (20×20 cm) plates,
precoated with silica gel (without fluorescent indicator) were purchased from
Macherey-Nagel (Düren, Germany). A fish oil standard (PUFA n-3) was supplied by
Supelco (Supelco Park, Bellefonte, PA, USA). Delphinidin-3-O-glucoside (D3G),
cyanidin-3-O-glucoside (C3G) and malvidin-3-O-glucoside (M3G) were obtainedfrom Extrasynthese (Genay, France). Palm oil (PO) and rapeseed oil (RO) were
obtained from William Hodgson & Co (Congleton, UK). All HPLC-grade solvents for
chromatography and solvents for extraction (proanalysis quality) were purchased from
Fisher Scientific (Fisher Scientific UK Ltd). The test polyphenolic compoundswere dissolved
in DMSO (Carl Roth, Karlsruhe, Germany), and stock solutions were stored at−80°C
until usage.
2.2. Animals and diets
All experimental procedures and protocols used in this study were reviewed and
approved by the Animal Welfare and Ethical Review Body and were conducted
according to the specifications of the United Kingdom Animals (Scientific Procedures)
Act, 1986.
Male Wistar rats aged 7–8 weeks were purchased from Charles River Laboratories
(Margate, UK). Rats were housed two per cage and under conditions of constant
temperature (21±2°C), humidity (55%±10%) and a standard light–dark cycle (12 h/12 h)
and were fed a standard RM3 diet (Special Diet Services, UK) while acclimatizing.
Rats were given food and water ad libitum. The test diets were prepared by replacing
the fat content by PO or RO into the standard purified diet for rodents D12450B
(Research Diets Inc, New Brunswick, NJ, USA). PO was chosen as the control oil as
it contains only trace amounts of ALA and has a high SFA content typical of a
Westernized-type diet. RO is a commonly consumed rich source of ALA which
typically constitutes around 10% of its total fatty acids. The nutrient composition of
the experimental diets and the fatty acid composition of the dietary fats are given in
Supplementary Tables 1 and 2, respectively.
Rats were randomly distributed into four groups of 10 animals each, in a 2×2
factorial design. Two groups of rats were fed the diet without supplementation (PO and
RO), whereas the other two received the same diets supplemented with 240mg/kg diet
of dietary ACNs (PO+ACN and RO+ACN). The ACN fraction was prepared by extracting
ACNs from blueberries giving rise to a prepurified extract. HPLC analysis [17,18]
indicated that the diet was composed of 38.3% of delphinidin-3-O-β-glucopyranoside,
34.7% of malvidin-3-O-β-glucopyranoside, 18.8% of petunidin-3-O-β-glucopyranoside,
6.7% of cyanidin-3-O-β-glucopyranoside and 1.4% of peonidin 3-O-β-glucopyranoside).
No ACNs were detected in the RO and PO control diets. Body weight and food intake
were recorded three times a week. At the end of the 8-week intervention, rats were
anesthetized with an overdose of sodium pentobarbital (150 mg/kg, i.p,) and blood
was drawn by cardiac puncture into serum separation tubes (SST, Becton Dickinson,
UK). Rats were then transcardially perfused with an ice cold saline solution (100 ml)
213D. Vauzour et al. / Journal of Nutritional Biochemistry 26 (2015) 211–218containing 10 U/ml of sodium heparin. Serum was obtained after centrifugation
(10 min, 1300×g, room temperature) and immediately frozen at−80°C until analysis.
A portion of liver was rapidly removed, rinsed with ice-cold 150 mmol/L NaCl, blotted
and weighed. Individual aliquots were snap-frozen and stored at −80°C before
extraction of lipids.
2.3. Human plasma samples
Stored plasma samples from our completed randomized control trial were used to
examine the impact of ACNs on fatty acid status in humans. In this placebo-controlled
intervention designed to examine the impact of ACN-rich elderberry extract on
biomarkers of cardiovascular health, postmenopausal women consumed 500 mg/day
ACNs as cyanidin glycosides (from elderberry) for 12 weeks. The study design has been
previously described in detail [16]. The ACN content of the elderberry (Sambucus nigra)
extract was previously established as 250 mg ACN per gram of extract [16],
predominantly consisting of cyanidin-3-glucoside (53.5%) and cyanidin-3-sambubioside
(39.5%) [19]. Elderberries are also reported to contain low amounts of cyanidin-3-
sambubioside-5-glucoside (6%) and cyanidin-3,5-diglucoside (1%) [20]. Volunteers were
on average 8y postmenopausal with the groups matched for age and body mass index
(BMI),withameanageandBMIof58.3years and24.3kg/m2and58.1yearsand25.1kg/m2in
the placebo and ACN groups, respectively. At the beginning and end of the intervention,
participants provided a 12-h fasting blood sample collected into K2-EDTA. Plasma
was obtained by centrifugation at 1500×g for 15 min within 30min of collection and stored
at−80°C awaiting analysis.
2.4. HepG2 cell culture and treatments
The HepG2 liver cell line (LGC Standards) were maintained in Dulbecco's modified
Eagle's medium (DMEM) containing 4.5 g/L glucose, 4 mmol/L L-glutamine, 1 mmol/L
sodium pyruvate, 10% heat-inactivated fetal calf serum (FCS), 100 U/ml penicillin and
100 μg/ml streptomycin (PAA, Coelbe, Germany). Cells were grown in 5% CO2 at 37°C
under a humidified atmosphere. All cell-culture plasticware was purchased from
Sarstedt (Nuembrecht, Germany) unless otherwise stated. For the experiments, cells
were seeded (2×106 cells/well) into 6-well plates and cultured for 24 h in routine
culture medium at 37°C, under 5% CO2 and 95% air. The routine culture medium was
aspirated and the HepG2 cells were washed twice with phosphate-buffered saline and
cultured for 24 h in serum-free DMEM. Serum-free conditions were used in order to
avoid potential flavonoid–protein interaction [21] and to minimize interference of
other fatty acids present in FCS [22]. Individual aliquots of ALA-BSA (1:2 molar ratio,
50 μMALA)working solution alone (control) or supplemented with D3G, C3G andM3G
and their metabolites, GA, SYA and PCA (5 μM) were added to the HepG2 cell culture.
Time points and ALA concentration were chosen according to previously published
data [23,24]. ACNs subclasses were chosen as they represent the main dietary ACNs
and/or the main ACN metabolites found in the systemic circulation [25]. Concentra-
tions of ALA and ACN metabolites of 50 and 5 μM were chosen as they represent
achievable levels in human plasma and therefore a physiologically relevant hepatocyte
exposure [26,27]. Assays vehicle controls were included which did not affect any of the
parameters measured.
Cytotoxicity of the pure ACNs and their metabolites was determined via the
Neutral Red Assay [28]. Briefly, HepG2 cells were seeded in 24-well plates, precultured
for 24 h and treated with 25 and 50 μM of the test compounds for 48 h. The culture
medium containing the test substances was replaced with fresh serum-containing
medium including 50 μg/ml of Neutral Red (Carl Roth). After incubation for 3 h, the
medium was removed and the cells were extracted using a solution comprising
50:49:1 (vol/vol/vol) ethanol, water and glacial acetic acid. The absorbance was
measured in a plate reader (Labsystems, Helsinki, Finland) at 540 nm.
2.5. RNA isolation and real-time PCR
For RNA-isolation, HepG2 cells were precultured in 6-well plates for 24 h.
Subsequently, cells were serum starved for 24 h. Then cells were incubated for 48 h
with 50 µmol/L of the test compounds in serum free medium supplemented with ALA-
BSA. RNA was isolated with TRIfast following the manufacturer's protocol (Peqlab,
Hamburg, Germany). FADS2 and GAPDH primers were designed by primer3 software
with the following sequences: HuFADS2: ACA AGG ATC CCG ATG TGA AC (forward) and
TTC GTG CTG GTG ATT GTA GG (reverse); HuGAPDH: CAA TGA CCC CTT CAT TGA CC
(forward) and GAT CTC GCT CCT GGA AGA TG (reverse) (MWG Biotech, Ebersberg,
Germany). Real-time PCR was performed using Sensi-Mix one-step kit (Quantace,
Berlin, Germany).
For liver samples, total RNA was extracted with Trizol reagent (Invitrogen Life
Technologies, Paisley, UK). FADS2 and GAPDH primers were designed by primer3
software with the following sequences: rnFADS2: CCC AAG CTG GAT GGC TAC AA
(forward) and TGC AGG CTC TTT ATG TCG GG (reverse); rnGAPDH: GTC TAC TGG CGT
CTT CAC CA (forward) and GTG GCA GTG ATG GCA TGG AC (reverse) (Life Technology,
UK). The reverse transcriptase reaction was performed with 5 μg of total RNA using
SuperScript II Reverse Transcriptase (Invitrogen) and oligo (dT) primers. The RT-qPCR
analysis was performed using a PCR master mix with SYBR green (PrimerDesign Ltd,
Southampton, UK) with an Applied Biosystems 7500 Real time PCR. Results werenormalized using GAPDH as a reference. After normalization, all results are expressed
as a percentage of control as means and standard error means (S.E.M).
2.6. Lipid and fatty acid analysis
The fatty acid composition of the HepG2 cells was determined by GC as described
previously [29]. Briefly, after a period of 24 and 48 h, the medium was aspirated and the
adherent cellswere removed from the platesusing aplastic tissue culture plate scraper and
centrifuged for5minat 2000×g. After centrifugation, theharvestedcellswere resuspended
in 200 μL 0.2 M NaCl and cell lipids were extracted using 1 ml chloroform/methanol (2:1,
vol/vol). Fatty acidmethyl esters (FAMEs)were synthesizedby incubationwithmethanolic
sulphuric acid (2% H2SO4, vol/vol) at 50°C for 2 h followed by extraction with hexane.
FAMEswere resolved on a 7820AAgilent gas chromatograph (Agilent) equippedwith a 60
m×250 μM×0.2 μM Agilent HP-88 fused silica capillary column using the following
temperature protocol: initial temperature 115°C, ramp 8°C/min to 145°C (26 min), ramp
2°C/min to 220°C (5min). FAMEs were identified and quantified by comparisonwith ALA,
EPA and DHAmethyl ester standards run previously. Chromatograms were recordedwith
an EZChrom Elite data system and results are presented as percentage of total fatty acids.
For human and rodent samples, total lipids were extracted from 500 μl of plasma or
300 mg of liver with chloroform/methanol (2:1 vol/vol) containing 0.01% BHT as
antioxidant [30]. The organic solvent was evaporated under a stream of nitrogen and
the lipid content was determined gravimetrically. Two milligrams of the total lipid
fraction (TL) was subjected to acid-catalyzed transmethylation for 16 h at 50°C, using 1
ml of toluene and 2 ml of 1% sulphuric acid (vol/vol) in methanol. Prior to
transmethylation, nonadecanoic acid (19:0) (5% of the total lipid analyzed), was
added as internal standard to the lipid extracts. The resultant FAMEs were purified by
TLC and visualized under spraying with 1% iodine in chloroform [31]. After elution,
FAMEs were separated and quantified by gas–liquid chromatography using a Hewlett
Packard 5890 GC and a SGE BPX70 capillary GC column (30 m×0.22 mm I.D.; SGE UK
Ltd) with helium as carrier gas and using on-column injection. The temperature
gradient started at 115°C for 3 min, then went to 200°C at 2°C/min, 2 min at 200°C, and
then to 240°C at 60°C/min. After 5 min at 240°C, it cooled down to 115°C and
equilibrated for 3 min before the next injection. Individual methyl esters were
identified by reference to authentic standards and to well-characterized fish oil
(PUFA-3 from menhaden oil; Supelco). Data were collected and processed using GC
Chemstation (version B04-02).
2.7. FADS2 activity index
The activity of FADS2 (also termed Δ6-desaturase) was estimated by the ratio
18:3n-3/18:2n-6 in the human samples [32].
2.8. Statistical analysis
Results are presented as means±S.D. with significance at Pb.05. The data were
checked for normal distribution with the one-sample Kolmogorov–Smirnoff test as
well as for homogeneity of variance with the Levene test and were log-transformed
where necessary before statistical analysis. Two-way analysis of variance (ANOVA)was
used to test effects of dietary fat type, supplementation with ACNs and their interaction
on variables in the rodent study or time, supplementation with ACNs/ACNs-rich food
and their interaction on variables in the human trial and the cell work. The differences
between means were tested using the Tukey's multiple comparison test when the
F value was significant [33]. One-way ANOVA was used to test the effects of the type of
fat and the ACNs on the growth parameters, liver weight and desaturase mRNA levels.
The statistical analysis was performed by using the SPSS package (version 16.0; SPSS
Inc., Chicago, IL, USA).
3. Results
3.1. Rodent study
There was a significant increase in body weight over the 8-week
time course of the experiment [F(7,60)=557.20, Pb.001), but no
difference in total body or liver weight, body weight gain, feed
efficiency ratios or food intake between diet groups (Table 1). On
average (expressed as mg/day/kg body weight), the PO group
consumed 244.4, 9.0 and 0, the PO+ACN group 254.0, 9.4 and 11.3;
the RO group, 270.5, 1119.6 and 0; and the RO+ACN group, 264.7,
1095.8 and 11.2, of LA, ALA, and ACN respectively. There were no
significant intergroup differences in LA intakes (PN.05).
Although a significantly higher level of serum ALA following RO
consumption was observed [F(1,32)=4.56, P=.041] (Table 2a), no
significant differences were found in the liver between groups
[F(1,34)=0.02, P=.89] (Table 2b). EPA (% of total fatty acids) levels
were approximately six-fold and eight-fold higher in serum and liver
Table 1
Growth parameters and liver weight.a,b
Growth parameters PO PO+ACN RO RO+ACN
Initial body weight (g) 376.4±28.9 369.8±22.5 355.3±27.9 355.3±19.3
Final body weight (g) 601.0±55.3 601.6±46.8 556.3±76.5 568.5±49.7
Body weight gain (g) 224.6±31.3 231.8±34.2 201.0±56.4 213.2±32.4
Food intake (g/day) 27.2±2.1 28.3±1.7 26.4±1.8 26.4±1.1
ACN intake (mg/day/kg) 0 11.3±1.7 0 11.2±1.2
Feed efficacy ratio 0.15±0.0 0.15±0.0 0.14± 0.0 0.14±0.0
Dietary energy
intake (kJ/day)
438±34 455±28 426±30 424±18
Organ weight (g/100 g BW)
Liver 3.18±0.3 3.29±0.4 3.30±0.6 3.10±0.2
a Diets were rich in either rich in PO or RO, not supplemented (diets PO and RO) or
supplemented with 240 mg/kg ACNs (diets PO+ACN and RO+ACN).
b Values are means±S.D.; n=10.
Table 2
Main fatty acids (≥0.5%) from total lipids (weight %) of serum (a) and liver (b) of
animals after 8 weeks of feeding a diet containing PO, PO+ACN, RO or RO+ACN,
respectively.
Fatty acids PO RO P valuea
PO PO+ACN RO RO+ACN Lipid ACN L×ACN
(a) Serum
14:0 0.8±0.2 0.8±0.2 0.6±0.1 0.6±0.2 0.002 NS NS
16:0 25.7±4.1 25.3±4.9 22.7±2.1 23.0±2.7 0.037 NS NS
16:1 n7 4.3±2.2 4.0±1.1 3.8±1.5 4.5±2.2 NS NS NS
18:0 12.1±4.0 12.5±2.4 11.7±1.4 11.3±1.1 NS NS NS
18:1b 21.9±5.9 21.2±3.6 16.5±2.4 17.5±2.9 0.003 NS NS
18:2 n6 9.8±4.5 10.4±1.7 16.0±5.4 14.6±4.1 0.001 NS NS
18:3 n3 1.6±1.1 1.4±1.1 2.8±1.7 2.2±1.1 0.041 NS NS
20:4 n6 15.3±3.0 16.4±4.0 12.0±2.2 11.9±3.5 0.002 NS NS
20:5 n3 0.4±0.2 0.5±0.1 2.7±0.8 2.5±0.7 0.000 NS NS
22:5 n3 0.2±0.1 0.2±0.1 1.0±0.1 1.0±0.1 0.000 NS NS
24:1 0.4±0.3 0.3±0.1 1.1±0.5 1.0±0.4 0.000 NS NS
22:6 n3 2.4±0.7 2.1±0.5 5.0±0.8 5.6±1.2 0.000 NS NS
Total n-3 PUFA 4.7±2.0 4.6±1.4 10.8±2.5 11.2±3.0 0.000 NS NS
Total n-6 PUFA 27.6±6.7 29.2±5.1 30.3±6.4 28.5±6.3 NS NS NS
n-3/n-6
PUFA ratio
0.2±0.1 0.2±0.1 0.4±0.2 0.4±0.2 0.000 NS NS
(b) Liver
14:0 0.9±0.3 0.9±0.2 0.8±0.3 0.6±0.2 0.008 NS NS
16:0 29.4±5.2 28.7±3.0 26.2±2.0 25.5±2.7 0.012 NS NS
16:1 n7 6.3±2.7 6.1±2.2 5.2±2.0 4.5±1.3 NS NS NS
18:0 11.8±3.6 11.8±4.1 15.0±2.8 15.4±2.9 0.004 NS NS
18:1b 28.8±6.7 30.0±7.1 20.3±4.8 20.2±3.7 0.000 NS NS
18:2 n6 5.8±3.3 5.7±2.0 10.2±4.3 9.7±2.8 0.000 NS NS
18:3 n3 1.2±0.8 0.9±0.5 1.1±0.5 1.5±0.5 NS NS NS
20:4 n6 8.9±3.9 9.6±3.5 8.0±2.4 8.2±1.9 NS NS NS
20:5 n3 0.2±0.2 0.2±0.1 1.7±0.7 1.6±0.6 0.000 NS NS
22:5 n3 0.2±0.1 0.2±0.1 0.1±0.0 0.1±0.1 0.012 NS NS
24:1 0.3±0.2 0.3±0.2 1.1±0.4 1.1±0.2 0.000 NS NS
22:6 n3 3.3±1.7 3.2±1.2 7.2±2.2 7.7±2.6 0.000 NS NS
Total n-3 PUFA 5.0±2.8 4.7±1.6 10.2±2.5 11.2±3.7 0.000 NS NS
Total n-6 PUFA 16.4±7.2 17.0±5.7 20.1±6.1 20.2±4.4 NS NS NS
n-3/n-6
PUFA ratio
0.29±0.1 0.3±0.1 0.58±0.3 0.60±0.3 0.001 NS NS
Results represent means±S.D. (n=10). Totals include some minor components not shown.
a Two-wayANOVA: lipid, significant influence of lipid source included in the treatment;
ACN, significant influence of ACNs; L×ACN, interaction; NS, not significant (PN.05).
b Contains n-9 and n-7 isomers.
214 D. Vauzour et al. / Journal of Nutritional Biochemistry 26 (2015) 211–218following RO (RO and RO+ACN) compared to the PO groups (PO and
PO+ACN) feeding [F(1,32)=129.02, Pb.001, and F(1,34)=70.32,
Pb.001, respectively], with two-fold higher DHA levels observed for
both serum and liver [F(1,32)=125.30, Pb.001, and F(1,34)=7.03,
P=.012, respectively]. These higher EPA, DHA and ALA levels were
reflected in the total n-3 PUFA content (Table 2a and b). A five-fold
increase in DPA, an intermediary between EPA and DHA, was
observed in the serum following RO (RO and RO+ACN) treatment
when compared to the PO groups (PO and PO+ACN) (Pb.001).
However, such modulation was not reflected in the liver where DPA
levels dropped by 50% following RO (RO and RO+ACN) treatments
(P=.001). Conversely, serum and liver myristic acid (C14:0) and
oleic acid (C18:1, n-9) levels were 20%–40% lower in the RO versus
PO group (Pb.05, Table 2a and b). No significant impact of the
inclusion of ACN in either the PO or RO diets on serum or liver fatty
acid status was observed (Table 2a and b).
No significant impact of the 8-week feeding PO and RO with or
without ACN on FADS2 gene expression in liver samples was evident
[F(3,20)=0.57, P=.64] (Fig. 2A).
3.2. Human study
Mean plasma ALA, EPA and DHA were 0.54%±0.17%, 1.15%±0.60%
and 2.52%±0.62% respectivelywith no significant differences in the fatty
acid profiles between the control and elderberry groups at baseline
(Table 3).We observed a significant increase in ALA following a 12-week
intervention in both the control and ACNs groups [F(1,23)=6.99,
P=.015]. No significant impact of the elderberry intervention on EPA,
DPA or DHA status was evident (Table 3).
3.3. Cell study
None of the ACNs (C3G, M3G and D3G) or their breakdown
products [GA, PCA and SYA] demonstrated any cytotoxicity toward
HepG2 cells at the highest concentration of 50 μM used in these
experiments (data not shown). A significant increase in both ALA and
EPA levels (Pb.001) was evident following the addition of complexed
BSA-ALA 50 μM in the cell culture medium. These data were
supported by a two-fold increase (P=.014) in FADS2 mRNA levels
following ALA addition (Fig. 2B). No significant effect was observed
for any of the treatments on DHA levels.
Pretreating HepG2 cells with D3G (5 μM) significantly decreased
EPA levels by 43% and 61% following 24- or 48-h incubation,
respectively (Pb.0001) (Table 4). In agreement with this observation,
a significant decrease in bothDPA levels and FADS2mRNA levelwas also
observed following treatmentwithD3G (Table 4 and Fig. 2B). Conversely,
an increase in palmitic acid (C16:0, Pb.001) and stearic acid (C18:0,
Pb.001) levels was observed following 48-h treatment with D3G. No
significant effects were observed on fatty acid levels or FADS2 mRNA
levels in HepG2 cells challengedwith any other ACNs or their breakdown
metabolites (Table 4 and Fig. 2B).
4. Discussion
Recent prospective data suggest that the decreased risk of
cardiovascular disease associatedwith increased fruits and vegetables
intake [34–36] may be in large part attributable to intake of specific
flavonoids [36]. In particular, ACNs have been reported to decrease
hypertension [37] and to reduce the risk of myocardial infarction [38].
In observational studies, red wine (rich in ACNs) consumption has
been associated with higher plasma and tissue EPA and DHA levels
[10–13], with the only two available relevant rodent studies reporting
inconsistent findings [14,15]. One of the main limitations of the two
rodent studies [14,15] is the lack of purity of the tested compounds,
with ACNs-rich food containing not only ACNs but also otherflavonoid subclasses and phenolic acids. The present study was
therefore designed to determine the biological effects of purified
ACNs and their major degradation products, on both the quantity and
the quality of cell membranes, plasma and liver fatty acids in a series of
experiments carriedout in cells and rodents. In addition, stored samples
were used to examine for the first time the impact of ACNs-rich food
(elderberry extract, 500 mg/day ACNs as cyanidin glycosides) on fatty
acid status in a human intervention trial.
Fig. 2. (A) mRNA expression of FADS2 in the liver. Real-time quantitative PCR analysis of
mRNA expression of FADS2 in the liver of rats (n=8per group) fedwith PO or ROwith or
without ACNs (PO+ACN and RO+ACN). (B) mRNA expression of FADS2 in HepG2 cells.
Real-time quantitative PCR analysis of mRNA expression of FADS2 in HepG2 cells
following the addition of ALA, with or without anthocyanins or their breakdown
metabolites (n=3). Ctrl-BSA, control using BSA; Ctrl ALA, control using ALA (50 μM); C3G,
cyanindin-3-glucoside (5 μM); M3G, malvidin-3-glucoside (5 μM); D3G, dephinidin-3-
glucoside (5 μM); GA, gallic acid (5 μM); PCA, p-coumaric acid (5 μM); SYA, syringic acid
(5 μM). One-way ANOVA was used followed by Tukey's multiple comparison test. *Mean
values were significantly different compared with control-BSA (−ALA; Pb.05); #mean
values were significantly different compared with control+ALA (Pb.05).
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compared with the intake of other dietary flavonoids [39–41]. For a
human of 70-kg body weight, such intake corresponds to a daily
consumption of 2.6 to 3.1 mg per kg bodyweight, respectively. During
the course of our experiments in our rodent model, animals in the
ACN group ingested ~11 mg/kg/day. This ACN dose was equivalent to
2.6 mg/kg/day in humans (181±22 mg ACNs in a 70-kg person)
(respectively according to the human equivalent dose formula:
HED=animal dose in mg/kg×(animal weight in kg/human weight
in kg)0.33 [42,43]. Thus, the dietary intake of ACNs in our animal study
was reflective of dietary achievable ACN intakes in humans. However,
while ACNs intake was previously associated with 20%–35% and 10%–
20% increased plasma EPA and DHA levels, respectively [14], at similar
dose, we did not observe any serum or liver changes in the n-3 PUFA
profile following ACNs supplementation. One possible reason for this
apparent inconsistency may be attributable to the distribution profile
of the ACNs. Indeed, while themajor ACNs detected in the Toufektsian
study were mainly glucoside derivatives of cyanidin and pelargonidin[44], our diet contained a more diverse range of ACNs i.e. glucoside
derivatives of delphinidin, cyanidin, petunidin, peonidin andmalvidin
[44]. In addition to ACNs, the authors also reported the presence of
phenylpropanoids or flavonols [45], two other subclasses of polyphe-
nols, that may be partly responsible for the results observed both in
red wine drinkers [10] and animals [14].
Traditionally, ACNs were thought to have a very low bioavailability,
with b1% of the ingested amount reaching the plasma; however, some
recent studies reveal that the bioavailability of these compoundsmay be
underestimated. In particular, although intact glucosides have been
detected in severalmammals followingoral consumption [46,47], recent
evidence, however, suggests that the bioactivity of dietaryACNs is rather
likely to be mediated by their degradation products [27,48,49]. In order
to test this hypothesis and in our effort to screen dietary phytochemicals
for potential physiological effects, we chose the pure ACNs cyanidin-3-
glucoside (C3G), malvidin-3-glucoside (M3G), dephinidin-3-glucoside
(D3G) and some of their major gut microbiota degradation products
(i.e., GA, PCA andSYA) [25]. In our hands, C3G,M3G, or their degradation
products GA, PCA or SYA did not substantially affect the distribution
of fatty acid in HepG2 cells. However, supplementation of the culture
medium with D3G had a reducing effect on the proportion of EPA
following 48-h incubation (−60%, Pb.0001), further substantiated by
the concomitant inhibition of the Δ6-desaturase mRNA levels in our
cellular model (−26%, Pb.001). Delphinidin-rich foods, such as
blackcurrant, have been previously reported to significantly reduce
LC-PUFA in rodent liver tissues [50]. Since our rodent diet contains
significant amounts of delphinidin (~38%), it may be hypothesized it
could mask the overall impact of ACNs on DHA and EPA biosynthesis
by modulating the levels of the Δ6-desaturase. Further experiments
aiming at determining the exact activity of this particular compound
on LC-PUFA metabolism would however be necessary before drawing
solid conclusions.
In our experiments, as expected, rats fed an ACN-free diet plus RO
(rich in ALA) had higher plasma and liver EPA and DHA levels than
those fed with PO. Similarly, the addition of ALA 50 μM also increased
EPA levels and was paralleled with two-fold increases in FADS2
activity in HepG2 cells. These results are in agreement with previous
studies, where mammalian hepatocytes have been reported to
accumulate high levels of EPA in cell phospholipids within 1–2 days
following ALA supplementation [23,51]. However, both on our rodent
or cellular models, none of the ACNs tested had any modulatory
effects on LC n-3 PUFA acid biosynthesis. A possible confounding
effect could be the high background ALA content in the diets of the
rodents and in the cell media may have potentially ‘masked' any
up-regulation of EPA and DHA synthesis associated with ACNs.
However, while a more significant EPA level was previously
associated with red wine consumption in the low ALA diet group
[12], results derived from our rodent study showed no modulation of
LC-n-3 PUFAs in the PO+ACN diet group (low ALA diet group [12]).
Another possible consideration in our rodent and human trial is that
our animals and participants were males and postmenopausal
females, respectively, groups who are known to have substantially
lower endogenous EPA and DHA biosynthesis relative to females of
reproductive age [52]. Premenopausal females have a high evolu-
tionary need for DHA and an adequate overall LC n-3 in order to meet
the needs of potential pregnancies. Establishment of the impact of
ACN (or other flavonoids) on LC n-3 PUFA status in premenopausal
females would therefore be of interest.
In summary, our results indicate that ACNs intake is unlikely to be
a meaningful determinant on LC n-3 PUFA status in mammals and
suggest that their increasingly described positive impacts on a range
of health outcomes is unlikely to be related to altered fatty acid
metabolism. The current large deficit between worldwide fish oil
production and the supplies needed to meet recommended of EPA
and DHA intakes in humans merits a sustained research focus in this
Table 4
Effects of ALA, ACNs and their metabolites on the fatty acid composition of HepG2 cell membranes after 24- or 48-h incubation.a
Fatty acid Ctrl-BSA Ctrl ALA C3G M3G D3G
24 h 48 h 24 h 48 h 24 h 48 h 24 h 48 h 24 h 48 h
16:0 28.2±0.2 26.4±0.2 27.2±0.1 27.5±0.4 29.5±2.5 26.7±1.2 27.4±0.7 30.1±2.9 27.5±0.1 31.2±4.1b
16:1 4.9±0.7 4.4±0.8 3.0±0.0c 2.6±0.2c 2.1±0.4 2.6±0.2 3.0±0.1 2.3±0.4 2.7±0.0 1.5±0.8b
18:0 22.3±1.7 22.0±1.3 23.2±1.3 24.2±1.3 29.7±8.5 23.0±1.0 22.9±1.7 29.8±7.4 22.5±2.0 32.7±10b
18:1 36.7±1.5 39.8±1.1 28.2±0.2c 29.9±0.2c 23.1±6.0 31.2±2.0 29.9±1.1 23.7±6.9 27.8±0.2 20.5±10.3b
18:2n6 3.1±0.5 3.0±0.4 3.3±0.9 3.2±0.7 2.5±0.0 3.5±1.2 3.2±0.7 2.6±0.4 3.4±0.7 2.0±0.4
18:3n3 0.2±0.2 0.1±0.0 7.9±1.8c 5.2±0.6c 7.1±3.5 5.9±1.5 6.6±2.6 4.9±1.3 9.1±2.4 4.7±2.8
20:0 0.3±0.0 0.3±0.1 0.3±0.1 0.3±0.1 0.4±0.1 0.3±0.1 0.3±0.1 0.3±0.1 0.3±0.1 0.3±0.1
20:1 0.8±0.1 0.9±0.2 0.7±0.1 0.7±0.1c 0.5±0.0 0.6±0.1 0.6±0.1 0.5±0.1 0.6±0.1 0.4±0.1b
20:4n6 1.6±0.1 1.6±0.1 2.8±0.1 2.8±0.1 2.5±0.7 3.1±0.4 2.8±0.0 2.2±0.6 3.3±0.2 2.4±1.2
20:5n3 0.3±0.0 0.2±0.0 1.9±0.6c 2.3±1.0c 1.1±0.5 1.6±0.7 1.9±0.5 2.0±1.3 1.1±0.3 0.9±0.6b
24:1 0.2±0.0 0.3±0.0 0.3±0.0 0.3±0.1 0.3±0.1 0.3±0.0 0.3±0.1 0.3±0.1 0.2±0.1 0.3±0.0
22:6n3 1.0±0.0 0.8±0.0 0.9±0.1 0.8±0.1 0.9±0.2 0.8±0.1 0.8±0.0 0.9±0.1 1.0±0.1 3.0±2.2
n-3 PUFA 1.5±0.2 1.1±0.0 10.7±2.5c 8.3±1.7c 9.2±4.2 8.3±1.8 9.3±3.2 7.8±2.7 11.2±2.6 8.6±1.2
n-6 PUFA 4.7±0.6 4.6±0.6 6.1±0.9 5.9±0.9 5.0±0.7 6.6±1.1 6.0±0.7 4.8±0.8 6.8±0.5 4.3±1.5b
n-3/n-6 ratio 0.3±0.1 0.2±0.0 1.8±0.7c 1.5±0.5c 1.8±0.6 1.3±0.4 1.6±0.7 1.6±0.4 1.7±0.5 2.2±0.5
Fatty acid GA PCA SYA P valued
24 h 48 h 24 h 48 h 24 h 48 h Time Treatment T×T
16:0 27.0±0.2 29.7±2.4 27.3±0.2 26.3±0.5 27.4±0.1 26.9±0.7 NS NS 0.004
16:1 3.0±0.0 2.0±0.6 3.0±0.1 2.8±0.1 3.2±0.1 2.9±0.1 0.000 0.000 0.030
18:0 21.5±1.8 30.9±7.5 21.2±1.5 22.4±0.8 20.8±0.9 22.9±0.7 0.03 NS 0.020
18:1 29.2±0.3 23.6±6.2 29.8±0.2 32.0±0.3 30.5±0.8 31.6±0.6 NS 0.000 0.009
18:2n6 3.5±0.8 2.5±0.1 3.5±0.9 3.3±0.8 3.5±0.8 3.2±0.7 NS NS NS
18:3n3 8.3±1.6 5.0±1.6 8.3±1.9 5.4±0.6 7.7±1.7 5.0±0.9 0.000 0.000 NS
20:0 0.3±0.1 0.3±0.1 0.3±0.1 0.3±0.1 0.3±0.1 0.3±0.1 NS NS NS
20:1 0.7±0.1 0.4±0.0 0.6±0.1 0.7±0.1 0.4±0.2b 0.7±0.1 NS 0.000 0.003
20:4n6 3.3±0.2 2.5±0.3 3.0±0.0 3.0±0.2 2.9±0.0 2.7±0.2 0.04 0.000 0.020
20:5n3 1.6±0.5 1.8±1.1 1.6±0.5 2.2±0.9 1.9±0.7 2.3±1.0 NS 0.001 NS
24:1 0.2±0.0 0.2±0.0 0.3±0.0 0.3±0.0 0.2±0.0 0.3±0.0 NS NS NS
22:6n3 0.9±0.1 0.6±0.2 0.8±0.0 0.8±0.0 0.8±0.0 0.8±0.0 0.000 NS 0.040
n-3 PUFA 10.8±2.0 7.4±2.9 10.7±2.4 8.4±1.6 10.4±2.3 8.1±1.9 0.006 0.000 NS
n-6 PUFA 6.8±0.5 5.0±0.1 6.5±0.9 6.3±1.0 6.4±0.9 5.9±1.0 0.020 0.030 0.003
n-3/n-6 ratio 1.6±0.4 1.5±0.5 1.7±0.6 1.4±0.5 1.7±0.6 1.5±0.6 NS 0.000 NS
Ctrl-BSA, control using BSA; Ctrl ALA, control using ALA (50 μM); C3G, cyaniding-3-glucoside (5 μM); M3G, malvidin-3-glucoside (5 μM); D3G, dephinidin-3-glucoside (5 μM); GA
(5 μM); PCA, p-coumaric acid (5 μM); SYA, syringic acid (5 μM).
a Values are means±S.D. (n=3).
b Mean values were significantly different compared with control-ALA (Pb.05).
c Mean values were significantly different compared with control-BSA (Pb.05).
d Two-way ANOVA: time, significant influence of incubation time (24 h or 48 h) on fatty acid composition; Treatment, significant influence of BSA, ALA, ACNs or their metabolites
on fatty acid composition; T×T, interaction. NS, not significant (PN.05).
Table 3
Main fatty acids (≥0.5%) from total lipids (weight %) of plasma from a human randomized controlled trial where participants consumed an elderberry extract or a placebo for 12
weeks.
Fatty acid Control Elderberry P valuea
Week 0 Week 12 Week 0 Week 12 Time ACN T×ACN
14:0 10.62±4.5 9.05±4.8 8.76±3.0 8.45±4.7 NS NS NS
16:0 18.82±1.6 18.58±1.5 19.53±1.6 20.33±1.5 NS 0.014 NS
16:1b 2.01±0.5 2.25±0.6 2.43±0.6 2.76±0.7 NS 0.010 NS
18:0 6.95±0.6 6.97±0.5 6.77±0.8 7.41±1.0 NS NS NS
18:1b 17.96±2.0 18.00±2.2 19.14±1.7 18.96±2.6 NS NS NS
18:2n6 24.64±4.0 25.90±3.2 24.52±3.8 22.48±3.5 NS NS NS
18:3n3 0.49±0.2 0.67±0.2 0.59±0.2 0.65±0.2 0.015 NS NS
20:3n6 1.42±0.5 1.31±0.3 1.34±0.6 1.34±0.3 NS NS NS
20:4n6 5.38±1.7 5.53±1.4 5.91±1.8 5.28±1.3 NS NS NS
20:5n3 1.29±0.7 1.31±1.0 0.99±0.5 1.31±1.1 NS NS NS
22:5n3 0.60±0.1 0.58±0.1 0.58±0.2 0.58±0.2 NS NS NS
22:6n3 2.67±0.7 2.51±0.9 2.37±0.6 2.49±1.0 NS NS NS
Total n-3 PUFA 1.26±0.3 1.27±0.5 1.13±0.3 1.26±0.5 NS NS NS
Total n-6 PUFA 4.61±0.7 4.84±0.6 4.67±0.5 4.39±0.6 NS NS NS
n-3/n-6 PUFA ratio 0.28±0.1 0.26±0.1 0.24±0.1 0.29±0.1 NS NS NS
Δ6 (18:3 n-6/18:2 n-6) 0.02±0.0 0.02±0.0 0.02±0.0 0.03±0.0 0.017 NS NS
Values are means±S.D. (n=13). Totals include some minor components not shown.
a Two-way ANOVA: time, significant influence of duration of the trial; ACN, significant influence of ACNs; T×ACN, interaction; NS, not significant (PN.05).
b Contains n-9 and n-7 isomers.
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which may increase EPA and DHA biosynthesis, bioavailability and
tissue retention in fish and mammals, and the use of GM vegetable oil
sources as a non-marine source of EPA/DHA.
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